Elise C. Kohn

机构：National Institutes of Health, National Cancer Institute, National Cancer Institute · ORCID：0000-0002-8631-9762

发表论文 508 篇 · 总被引 29222 次 · h-index 82

代表论文

• Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors (2024 · New England Journal of Medicine · 被引 158)
• Vaccination of Adults With Cancer: ASCO Guideline (2024 · Journal of Clinical Oncology · 被引 122)
• LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) (2023 · Annals of Oncology · 被引 28)
• Top advances of the year: Ovarian cancer (2023 · Cancer · 被引 27)
• Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005 (2024 · Journal of Clinical Oncology · 被引 23)
• Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses (2024 · JCO Precision Oncology · 被引 22)